For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 114 | 5,944* | 570 | 3,871 |
| General and administrative | 5,425 | 3,286* | 3,027 | 4,095 |
| Acquired in-process research and development | 22,180 | - | - | - |
| Loss from operations | -27,719 | -9,230* | -3,597 | -7,966 |
| Interest expense | 0 | 138* | 0 | 46 |
| Interest income and other income (expense), net | 23 | 178* | 86 | 142 |
| Total other income (expense), net | 23 | 40* | 86 | 96 |
| Provision for income taxes | 0 | 0* | 0 | 0 |
| Net loss | -27,696 | -9,190 | -3,511 | -7,870 |
| Basic EPS | -2.53 | -2.185 | -0.79 | -2.07 |
| Diluted EPS | -2.53 | -2.185 | -0.79 | -2.07 |
| Basic Average Shares | 10,931,593 | 4,206,132 | 4,440,111 | 3,802,956 |
| Diluted Average Shares | 10,931,593 | 4,206,132 | 4,440,111 | 3,802,956 |
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)